Montrusco Bolton Investments Inc. Raises Stock Position in Zoetis Inc. $ZTS

Key Points

• Montrusco Bolton raised its stake by 256.7% in Q4 to 2,168,078 shares (about $266.9M), equal to ~0.49% of Zoetis and roughly 3.3% of the fund's portfolio (its 9th largest holding).
• Zoetis beat the quarter with EPS of $1.48 (vs. $1.40 consensus) and $2.39B revenue, and set FY2026 guidance of 7.00–7.10 EPS (sell-side consensus ~7.02).
• The company declared a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield) and has mixed analyst coverage with a MarketBeat consensus rating of "Hold" and a $152.25 price target.

Montrusco Bolton Investments Inc. lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 256.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,168,078 shares of the company's stock after purchasing an additional 1,560,314 shares during the period. Zoetis comprises approximately 3.3% of Montrusco Bolton Investments Inc.'s portfolio, making the stock its 9th biggest holding. Montrusco Bolton Investments Inc. owned about 0.49% of Zoetis worth $266,888,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in ZTS. Diamond Hill Capital Management Inc. bought a new position in shares of Zoetis in the third quarter worth approximately $394,010,000. Nordea Investment Management AB boosted its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock valued at $394,746,000 after acquiring an additional 1,227,085 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company's stock valued at $400,619,000 after acquiring an additional 1,191,840 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Zoetis by 342.1% in the third quarter. First Trust Advisors LP now owns 1,485,459 shares of the company's stock valued at $217,352,000 after acquiring an additional 1,149,467 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

ZTS opened at $116.92 on Friday. The stock has a 50-day moving average price of $120.83 and a 200-day moving average price of $125.53. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market cap of $49.18 billion, a PE ratio of 19.42, a P/E/G ratio of 1.77 and a beta of 0.98. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts predict that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's payout ratio is currently 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent analyst reports. Citigroup initiated coverage on shares of Zoetis in a report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price target on the stock. BTIG Research reiterated a "buy" rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Finally, Piper Sandler reissued a "neutral" rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $152.25.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.